2 3 7 8-Tetrachlorodibenzo-P-Dioxin Aluminum Oxide
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- 2 3 7 8-Tetrachlorodibenzo-P-Dioxin Aluminum Oxide
- Multi-Substance Entry (20 Components): Insufficient Data for Drug Repurposing Evaluation
Multi-Substance Entry (20 Components): Insufficient Data for Drug Repurposing Evaluation
One-Sentence Summary
This Evidence Pack contains 20 unrelated chemical substances consolidated into a single query entry (including 2,3,7,8-TCDD, benzene, glyphosate, formaldehyde, and others), rather than a single drug candidate. The TxGNN model returned no predicted indications, and there are no clinical trials or publications associated with this combined entry. This record cannot proceed to standard repurposing evaluation in its current form.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no predictions |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 (model prediction only — and no prediction was generated) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why This Prediction Cannot Be Evaluated
The inn field in this Evidence Pack is not a single drug. It is a semicolon-delimited list of 20 chemically unrelated substances:
| # | Substance | Category |
|---|---|---|
| 1 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) | Persistent organic pollutant / known carcinogen |
| 2 | Aluminum oxide | Industrial abrasive / excipient |
| 3 | Antipyrine | Analgesic / diagnostic agent |
| 4 | Benzene | Industrial solvent / known carcinogen (IARC Group 1) |
| 5 | Bisphenol A | Endocrine disruptor / plasticizer |
| 6 | Carbon disulfide | Industrial chemical / neurotoxin |
| 7 | Carboxymethylcellulose sodium | Pharmaceutical excipient |
| 8 | Diethylstilbestrol | Synthetic estrogen (withdrawn from most markets) |
| 9 | Estrone | Endogenous estrogen |
| 10 | Formaldehyde solution | Fixative / known carcinogen (IARC Group 1) |
| 11 | Garlic | Food substance / herbal supplement |
| 12 | Glyphosate | Herbicide |
| 13 | Kerosene | Petroleum distillate |
| 14 | Methylparaben | Preservative / excipient |
| 15 | Naphthalene | Industrial chemical / possible carcinogen |
| 16 | Paraffin | Wax / excipient |
| 17 | Phenacetin | Withdrawn analgesic (nephrotoxic) |
| 18 | Phenol | Antiseptic / industrial chemical |
| 19 | Polytetrafluoroethylene (PTFE) | Polymer / coating material |
| 20 | Ptelea trifoliata bark | Herbal botanical |
These substances share no common therapeutic indication, mechanism of action, or pharmacological class. They cannot be evaluated as a unified drug candidate. The TxGNN model’s failure to return any predictions is consistent with this data quality issue — the model could not identify a valid drug node in the knowledge graph for this concatenated query.
Conclusion and Next Steps
Decision: Hold
Rationale:
This entry is the result of a data pipeline error in which 20 unrelated substances were concatenated into the inn field of a single candidate record. There is no drug identity, no original indication, no predicted indication, and no safety profile to evaluate.
To proceed, the following is needed:
- Root cause investigation: Identify which upstream pipeline step produced this multi-substance concatenation (check
candidate_id: TW-UNKNOWN-multiand thev4generation process) - Re-submission as individual entries: Each substance that is a legitimate drug candidate (e.g., Antipyrine, Diethylstilbestrol, Estrone) should be submitted as a separate Evidence Pack with its own
candidate_id - Exclusion of non-drug substances: TCDD, benzene, glyphosate, kerosene, formaldehyde, and naphthalene are environmental toxins or industrial chemicals — these should be filtered out at the data ingestion stage before reaching the repurposing pipeline
- DrugBank ID validation gate: The pipeline should reject any entry with
drugbank_id: nulluntil a valid DrugBank ID is confirmed - MOA and regulatory data: For any legitimate candidates separated from this entry, DrugBank MOA and TFDA package insert data must be retrieved before safety evaluation can begin
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.